Status:
COMPLETED
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Lead Sponsor:
New Mexico Cancer Research Alliance
Collaborating Sponsors:
Genentech, Inc.
NYU Langone Health
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin). How Doxil is met...
Detailed Description
Avastin: Avastin is a humanized monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer). Avastin has been approved for the...
Eligibility Criteria
Inclusion
- Patients must be platinum resistant
- Patients will be included in the study based on the following criteria:
- No prior anthracycline use
- PS less or equal 2
- Lab values within certain limits (ANC greater 1000, platelets greater 100,000; ALT, AST 2 time ULN, creatinine less 2.0)
- No more than 3 prior chemotherapy regimens, only 2 of which can have included platinum-containing regimens
- Use of effective means of contraception in subjects of child-bearing potential
Exclusion
- Disease-Specific Exclusions:
- Evidence of complete or partial bowel obstruction
- Need for IV hydration or TPN
- Greater 2 prior abdominal surgeries
- History of gastrointestinal perforation
- Gastrointestinal perforation due to any other cause within the last 6 months
- General Medical Exclusions:
- Inability to comply with study and/or follow-up procedures
- Life expectancy of less than 12 weeks
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study
- Avastin-Specific Exclusions
- Inadequately controlled hypertension (defined as systolic blood pressure 150 and/or diastolic blood pressure greater 100 mmHg on antihypertensive medications)
- Any prior history of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)
- History of myocardial infarction or unstable angina within 6 months prior to study enrollment
- History of stroke or transient ischemic attack within 6 months prior to study enrollment
- Known CNS disease
- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- Symptomatic peripheral vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
- History of abdominal fistula, or intra-abdominal abscess within 6 months prior to study enrollment
- Serious, non-healing wound, ulcer, or bone fracture
- Proteinuria at screening as demonstrated by either:
- Urine protein:creatinine (UPC) ratio 1.0 at screening OR
- Urine dipstick for proteinuria greater or equal 2plus (patients discovered to have greater or equal 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate less or equal 1g of protein in 24 hours to be eligible)
- Known hypersensitivity to any component of Avastin
- Pregnant (positive pregnancy test) or lactating. No effective means of contraception (men and women) in subjects of child-bearing potential
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00945139
Start Date
March 1 2007
End Date
August 1 2011
Last Update
July 31 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico
Albuquerque, New Mexico, United States, 87106
2
New Mexico Cancer Care Associates
Santa Fe, New Mexico, United States, 87505
3
New York University Cancer Institute
New York, New York, United States, 10016